Skip to main content
. Author manuscript; available in PMC: 2016 Jun 15.
Published in final edited form as: Cancer Res. 2015 Apr 13;75(12):2489–2500. doi: 10.1158/0008-5472.CAN-14-3167

Figure 4. In vitro combination of AZD9291 with selumetinib induces more profound phenotype inhibition.

Figure 4

(A) PC9 and (B) NCI-H1975 cells were chronically treated for 34 days with DMSO, AZD9291, selumetinib or a combination of AZD9291 with selumetinib. Fold increase in cell number was monitored over time. Lysates from PC9 GR_1 (C) or NCI-H1975 (E) cells treated with AZD9291 and selumetinib alone or in combination for 48 hours were analysed by immunoblotting. PC9 GR_1 (D) or NCI-H1975 (F) cells were treated over 12 days with AZD9291 and selumetinib alone or in combination. Cells were fixed and cell number determined from nuclei count. Error bars represent standard deviation.